Estrogen-like agonist TTC-352, an anti-breast cancer drug with therapeutic potential.

Breast cancer affects one in eight women in the United States, and although there are many types of breast cancer, about 80 percent are classified as estrogen-positive (ER-positive).
this means that cancer cells have estrogen-sensitive subjects, i.e. estrogen, which promotes cancer growth.
to treat this type of breast cancer, some drugs can be used to stop the production of hormones in the body or interfere with the role of hormones on cancer cells, a treatment called hormone therapy.
, however, nearly half of women who received hormone therapy developed resistance.
recently, researchers at the University of Illinois at Chicago (UIC) developed a new breast cancer drug that can help stop the disease from progressing and is not toxic.
results were recently published in the journal Breast Cancer Research and Treatment.
Debra Tonetti, of the UIC School of Pharmacy, said: "Although there are many treatments for breast cancer, about half of women with ER-positive cancer are resistant to hormone therapy.
there are few therapies other than chemotherapy that work, but the toxic side effects of chemotherapy are particularly pronounced."
UIC's latest anti-breast cancer compound is TTC-352, a selective partial agonist for human estrogen- and estrogen-infestors.
preclinical studies have shown that TTC-352 can cause tumors to subside completely.
phase I clinical trials, 15 women with metastases breast cancer who had previously received several rounds of hormone therapy were included, in some cases, chemical therapy, including CDK4/6 inhibitors.
found that TTC-352 was safe even at the highest doses.
.